Karo Pharma AB (publ)
Karo Pharma AB (publ) (KARBF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
karbf · pe ratio · data through Jun 8, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Karo Pharma AB (publ)You KARBF | $1.5B | N/A | — | — |
 Biotest AG BIESF | $1.6B | 41.48x | +32.8% | $0.71 |
 Biotage AB (publ) BITGF | $1.2B | 46.23x | +48.1% | $3.55 |
 CompuGroup Medical SE & Co. KGaA CMPUY | $1.2B | 33.34x | +6.8% | $0.67 |
 CompuGroup Medical SE & Co. KGaA CMPVF | $1.7B | 52.49x | +68.1% | $0.55 |
 China Shineway Pharmaceutical Group Limited CSWYF | $816M | 5.56x | -82.2% | $1.26 |
 Drägerwerk AG & Co. KGaA DGWPF | $1.4B | 8.23x | -73.6% | $7.44 |
Industry Average 6 peers with valid PE | — | 31.22x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Karo Pharma AB (publ) (KARBF) measures how much investors pay for each dollar of the company's trailing earnings. KARBF's current PE ratio of N/A is calculated by dividing its stock price of $5.25 by its TTM earnings per share of —.
Frequently asked questions
KARBF pe ratio · 6 questionsKARBF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $5.25 and TTM EPS of —. Data sourced from Financial Modeling Prep via KARBF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Karo Pharma AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08